Ratings Med Life S.A.

Equities

M

ROMEDLACNOR6

End-of-day quote Bucharest S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4.13 ^RON	-0.48%		+2.48%	+3.77%

Apr. 03	Med Life S.A. (BVB:M) acquired an unknown majority stake in Personal Genetics Srl.	CI
Feb. 29	Med Life S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2025.
Sales forecast by analysts have been recently revised upwards.

Weaknesses

The company is in debt and has limited leeway for investment
The company appears highly valued given the size of its balance sheet.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MED LIFE S.A.	+3.77%	467M		C+
CVS HEALTH CORPORATION	-29.03%	85.35B		B-
HCA HEALTHCARE, INC.	+14.43%	81.95B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	28.99B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.41%	16.98B		B
FRESENIUS SE & CO. KGAA	-0.36%	16.85B		A-
QUEST DIAGNOSTICS INCORPORATED	-0.76%	15.35B		A-
FRESENIUS MEDICAL CARE AG	+4.32%	12.42B		A-
DAVITA INC.	+31.59%	12.19B		B-
PURE HEALTH HOLDING	-31.40%	11.89B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders